 | Up a level |
Schuler, M., Cassier, P., Penel, N., Cathomas, R., Richly, H., Schostak, M., Janitzky, A., Wermke, M., Nogova, L., Tai, D., Sayehli, C., Gruellich, C., Grande, E., Navarro, A., Park, S. H., Nogai, H., Bender, S., Ellinghaus, P. and Joerger, M. (2018). Rogaratinib in patients with advanced urothelial carcinomas selected for tumor FGFR mRNA expression and impact of mutations in the FGFR signaling pathway. Oncol. Res. Treat., 41. S. 321 - 322. BASEL: KARGER. ISSN 2296-5262
Schuler, M., Nogova, L., Heidenreich, A., Tai, D., Cassier, P., Richly, H., Cho, B. C., Sayehli, C. M., Navarro, A., Bender, S., Ocker, M., Nogai, H., Wagner, A., Ince, S., Ellinghaus, P. and Joerger, M. (2017). Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041